Mandate

Vinge advised Orexo on its divestment of Kibion

May 05, 2015

Orexo AB (publ) (Nasdaq Stockholm) has divested its subsidiary Kibion to a group of investors. Vinge advised Orexo.

The Vinge team included Erik Sjöman (partner, capital markets and M&A) and associates Christian Lindhé, Kristoffer Franzkeit and Cecilia Cronqvist.

Related

Vinge advises Active Biotech in connection with rights issue

Vinge advises Active Biotech AB (publ) in connection with a rights issue of approximately SEK 43 million.
November 29, 2024

Vinge advises ABGSC and SEB in connection with Europi’s inaugural issuance of green bonds

Vinge has advised the joint arrangers in connection with Europi Property Group AB (publ)’s (the "Company") inaugural issue of EUR 50 million senior unsecured green bonds within a framework of up to EUR 100 million. The bonds carry a floating interest rate of EURIBOR 3M + 5.00% and have a tenor of three years. The Company intends to apply for admission to trading of the new bonds on Nasdaq Transfer Market and the sustainable bond list of Nasdaq Stockholm.
November 29, 2024

Vinge advises Rieber & Søn in connection with its acquisition of Accept Försäkringsaktiebolag (publ)

Accept, with headquarter in Stockholm, has been an innovator in the Swedish insurance market since its formation in 1998. The company was the first with offering loss of income insurance and has since offered products that complement the general insurance offering. Today, Accept delivers web-based insurance solutions customised for its offering.
November 21, 2024